1. Scrip
  2. >>Business
  3. >>Strategy

Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations

Infectious Disease Partnering Head Patrick Schleck Describes Priorities

 
• By Mandy Jackson

Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.

magnifying glass

Roche Holding AG has a long history in infectious diseases, including the antibiotics Rocephin and Bactrim as well as the influenza antivirals Tamiflu and Xofluza, and the company has put its expertise to use in COVID-19 through testing of its arthritis biologic Actemra – though results have been mixed – and through partnerships for the development of novel treatments. Ultimately, Roche believes that it likely will take combinations of multiple drugs to mount the most effective attack against the novel coronavirus.

Patrick Schleck, global head of partnering for immunology and infectious diseases at Roche and Genentech, Inc. , described his...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 
• By Alaric DeArment

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 
• By Jessica Merrill

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.

Asia Deal Watch: JCR And Alexion Build Upon Existing Gene Therapy Alliances

 
• By Joseph Haas, Lisa Takagi, Sushmita Panda, and Anju Ghangurde

Plus deals involving TandemAI/Perpetual Medicines, Biocytogen/BeOne, Chugai/Gero, CStone/Istituto Gentili, Alembic/Utility, Brii/Joincare, HanchorBio/Henlius, Rakuten/Cyntec and more.